Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Vytorin ezetimibe/simvastatin: Additional Phase III data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Vytorin ezetimibe/simvastatin Business: Cardiovascular Molecular target: HMG-CoA reductase Description: Cholesterol absorption inhibitor plus HMG-CoA …

    Published on 3/23/2015
  • AKB-9778: Additional Phase Ib/IIa data

    Aerpio Therapeutics Inc., Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta Description: Tyrosine kinase receptor 2 (Tie2) …

    Published on 3/16/2015
  • Auryxia ferric citrate: Additional Phase III data

    Keryx Biopharmaceuticals Inc.(NASDAQ:KERX), New York, N.Y. Panion & BF Biotech Inc.(Taiwan:1760), Taipei, Taiwan Japan Tobacco Inc.(Tokyo:2914), Tokyo, Japan Torii Pharmaceutical Co. Ltd.(Tokyo:4551), Tokyo, Japan …

    Published on 3/16/2015
  • Dalantercept: Additional Phase II data

    Acceleron Pharma Inc.(NASDAQ:XLRN), Cambridge, Mass. Product: Dalantercept (ACE-041) Business: Cancer Molecular target: Activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2) Description: Angiogenesis inhibitor that …

    Published on 3/16/2015
  • Dexamethasone-loaded punctum plug: Phase III data

    Ocular Therapeutix Inc.(NASDAQ:OCUL), Bedford, Mass. Product: Dexamethasone-loaded punctum plug (OTX-DP) Business: Neurology Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained- and …

    Published on 3/16/2015
  • Egalet-001: Clinical trial data

    Egalet Corp.(NASDAQ:EGLT), Wayne, Pa. Product: Egalet-001 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Abuse-deterrent, extended-release, oral formulation of morphine Indication: …

    Published on 3/16/2015
  • Human neural stem cells: Phase II data

    Neuralstem Inc.(NYSE-M:CUR), Rockville, Md. Product: Human neural stem cells (hNSCs) (NSI-566, NSI-566RSC) Business: Neurology Molecular target: Not applicable Description: Human neural stem cells (hNSCs) Indication: …

    Published on 3/16/2015
  • Metadoxine ER: Phase II data

    Alcobra Ltd.(NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 3/16/2015
  • MicOryx: Phase I/IIa data

    Oryx GmbH & Co. KG, Baldham, Germany Product: MicOryx Business: Cancer Molecular target: NA Description: Vaccine comprised of 3 synthetic frameshift peptides: AIM2, HT001 and TAF1B Indication: Treat advanced …

    Published on 3/16/2015
  • MV-CHIK vaccine: Additional Phase I data

    Themis Bioscience GmbH, Vienna, Austria Product: MV-CHIK vaccine Business: Infectious Molecular target: NA Description: Vaccine developed using Thermaxyn technology that uses a single measles virus vector expressing the…

    Published on 3/16/2015
  • OBE001: Phase I data

    ObsEva S.A., Geneva, Switzerland Merck KGaA(Xetra:MRK), Darmstadt, Germany Product: OBE001 Business: Genitourinary Molecular target: Oxytocin (OXT) (OT) Description: Oxytocin (OXT; OT) receptor antagonist Indication: …

    Published on 3/16/2015
  • Pacritinib: Phase III data

    CTI BioPharma Corp.(NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Baxter International Inc.(NYSE:BAX), Deerfield, Ill. Product: Pacritinib (SB1518, ONX 0803) Business: Hematology Molecular target: Janus kinase-2 (JAK-2); FMS…

    Published on 3/16/2015
  • PEP-CMV: Phase I/II data

    Annias Immunotherapeutics Inc., Chapel Hill, N.C. Product: PEP-CMV Business: Cancer Molecular target: Human cytomegalovirus (CMV) phosphoprotein 65 Description: Autologous dendritic cells pulsed with human …

    Published on 3/16/2015
  • PSMA ADC: Additional Phase II data

    Progenics Pharmaceuticals Inc.(NASDAQ:PGNX), Tarrytown, N.Y. Product: PSMA ADC Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Antibody-drug conjugate (ADC) …

    Published on 3/16/2015
  • Secnidazole: Phase I data

    Symbiomix Therapeutics LLC, Newark, N.J. Product: Secnidazole (SYM-1219) Business: Infectious Molecular target: NA Description: 5-nitroimidazole antibiotic Indication: Treat bacterial vaginosis Endpoint: Safety and …

    Published on 3/16/2015
  • Secnidazole: Phase I data

    Symbiomix Therapeutics LLC, Newark, N.J. Product: Secnidazole (SYM-1219) Business: Infectious Molecular target: NA Description: 5-nitroimidazole antibiotic Indication: Treat bacterial vaginosis Endpoint: Safety and …

    Published on 3/16/2015
  • Tradipitant: Phase II data

    Vanda Pharmaceuticals Inc.(NASDAQ:VNDA), Washington, D.C. Eli Lilly and Co.(NYSE:LLY), Indianapolis, Ind. Product: Tradipitant (formerly LY686017, VLY-686) Business: Dermatology Molecular target: Neurokinin 1 (NK1) …

    Published on 3/16/2015
  • Unoprostone isopropyl: Phase III data

    R-Tech Ueno Ltd.(JASDAQ:4573), Tokyo, Japan Product: Unoprostone isopropyl (Rescula) (UF-021) Business: Ophthalmic Molecular target: Potassium channel KCa1.1 (KCNMA1) (SLO); Chloride channel 2 (CLCN2) (ClC-2) …

    Published on 3/16/2015
  • VicOryx: Phase I/IIa data

    Oryx GmbH & Co. KG, Baldham, Germany Product: VicOryx Business: Cancer Molecular target: Cyclin dependent kinase inhibitor 2A (CDKN2A) (INK4a) (ARF) (p16INK4a) Description: Vaccine comprised of a synthetic cyclin …

    Published on 3/16/2015
  • VM202: Phase II data

    ViroMed Co. Ltd.(KOSDAQ:084990), Seoul, South Korea Product: VM202 Business: Neurology Molecular target: NA Description: PCK vector encoding the engineered hepatocyte growth factor (HGF) gene Indication: Treat diabetic …

    Published on 3/16/2015
  • VT-464: Interim Phase I/II data

    Innocrin Pharmaceuticals Inc., Durham, N.C. Product: VT-464 Business: Cancer Molecular target: Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A); Androgen receptor Description: Non-steroidal dual …

    Published on 3/16/2015
  • XOMA 358: Phase I data

    Xoma Corp.(NASDAQ:XOMA), Berkeley, Calif. Product: XOMA 358 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Allosteric human IgG2 mAb that binds to insulin receptor (INSR) Indication…

    Published on 3/16/2015
  • AF-219: Phase II data

    Afferent Pharmaceuticals Inc., San Mateo, Calif. Roche(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: AF-219 (formerly R1646, RG1646, RO 4926219) Business: Genitourinary Molecular target: Purinergic receptor P2X …

    Published on 3/9/2015
  • Andexanet alfa: Phase III data

    Portola Pharmaceuticals Inc.(NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT4445, PRT064445) Business: Cardiovascular Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 3/9/2015
  • Contrave naltrexone SR/bupropion SR: Additional Phase III data

    Orexigen Therapeutics Inc.(NASDAQ:OREX), La Jolla, Calif. Product: Contrave naltrexone SR/bupropion SR (NB32)(Mysimba - EU) Business: Endocrine/Metabolic Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: …

    Published on 3/9/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993